These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D. Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849 [Abstract] [Full Text] [Related]
3. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma]. Humbert M. Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866 [No Abstract] [Full Text] [Related]
4. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM. J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478 [Abstract] [Full Text] [Related]
5. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M. Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [Abstract] [Full Text] [Related]
6. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219 [Abstract] [Full Text] [Related]
7. An evidence-based approach to the management of pulmonary arterial hypertension. Archer SL, Michelakis ED. Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209 [Abstract] [Full Text] [Related]
10. [Treatment of pulmonary arterial hypertension associated to systemic sclerosis]. Hachulla E. Rev Med Interne; 2004 Mar; 25(3):195-200. PubMed ID: 15049280 [Abstract] [Full Text] [Related]
11. [Systemic sclerosis: paths into the future]. Guillevin L. Presse Med; 2006 Dec; 35(12 Pt 2):1892-3. PubMed ID: 17159714 [No Abstract] [Full Text] [Related]
12. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Catapano-Minotti G, Corsonello A, Guadalupi G, Spani R, Antonelli-Incalzi R. Intern Med; 2008 Dec; 47(6):511-3. PubMed ID: 18344637 [Abstract] [Full Text] [Related]
13. [Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis]. Gocho K, Sugino K, Ota H, Kusano E, Takai Y, Homma S. Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):786-90. PubMed ID: 21066870 [Abstract] [Full Text] [Related]
16. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Beghetti M. Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006 [Abstract] [Full Text] [Related]
19. Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients. Low AJ, Fowler D, Manghani MK, Young I, Garsia R, Torzillo P, Youssef P, Celermajer DS. Intern Med J; 2013 Jan; 43(1):32-7. PubMed ID: 22032309 [Abstract] [Full Text] [Related]
20. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion? Brancaccio G, Toscano A, Bevilacqua M, Di Chiara L, Parisi F. Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133 [Abstract] [Full Text] [Related] Page: [Next] [New Search]